Healthcare Guidance
Guidance, reporting, patient handouts and more from MSDH
Therapeutics
- Paxlovid ordering, reporting and resources
- COVID-19 Therapeutics Decision Aid
- Outpatient Administration Guide for Healthcare Providers (HHS.gov) Federal Response to COVID-19: Therapeutics Clinical Implementation Guide
- All therapeutics resources
Healthcare Provider Guidance and Resources
- CDC Infection Control Recommendations for Healthcare Professionals During COVID-19
- NIH Clinical Guidelines: Therapies for High-Risk, Nonhospitalized Patients
- NIH Panel's Statement on Prioritizing the Use of Outpatient Therapies
- CDC Guidance for Healthcare Personnel with Potential COVID-19 Exposure
- Handout: What to Do After You Have Been Tested for COVID-19
- Handout: Home Isolation for Individuals with COVID-19
- CDC guidance related to COVID-19
Patient Handouts
Vaccination Providers
Reporting COVID-19
- Updated SARS-CoV-2 Reporting Requirements May 25, 2023
COVID-19 Therapeutics
Therapeutics currently authorized or approved for the treatment of mild to moderate COVID-19 include the oral antivirals Paxlovid and Lagevrio and the intravenous antiviral Veklury.
Overview of Therapeutics for the Prevention or Treatment of COVID-19 (HHS.gov)
Oral Antivirals
Ordering: The federal government has designed the Healthcare Provider Order Portal (HPOP) for management of COVID-19 therapeutics. Please place your order in HPOP. You will be able to see courses ordered for your site on your HPOP account. If you do not have an HPOP account, please contact C19Therapeutics@msdh.ms.gov
Required reporting:Courses administered (dispensed) and courses available of Paxlovid and Lagevrio should be entered into HPOP by the provider site at least twice per month, on the 15th and last day of the month. Timely and accurate inventory reporting is necessary for federal partners to determine subsequent state allocations.
Resources:
- PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers (FDA)
- Paxlovid Resources from Pfizer.com
- Paxlovid Package Insert
- Paxlovid fact sheet for healthcare providers (FDA)
- Paxlovid fact sheet for patients/caregivers (FDA)
- Lagevrio resources from Merck.com
- Lagevrio fact sheet for healthcare providers (FDA)
- Lagevrio fact sheet for patients/caregivers (FDA)
Therapeutics Locator
Use this interactive map to locate a facility that has one of the authorized therapeutics for COVID-19.
Monoclonal Antibody Therapy
There are no monoclonal antibodies currently authorized in the U.S. for the outpatient treatment of COVID-19.
The following monoclonal antibody products are no longer authorized for use in the U.S.:
- Bamlanivimab
- Bamlanivimab/Etesevimab
- Bebtelovimab
- REGEN-COV
- Sotrovimab
Evusheld
As of January 26, 2023, Evusheld is no longer authorized for Emergency use for pre-exposure prophylaxis (prevention) of COVID-19.
Remdesivir
Remdesivir has been studied in non-hospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease and is approved by the FDA for use in both hospitalized and non-hospitalized patients.
Ordering: Remdesivir is commercially available and should be ordered through standard pharmaceutical procurement processes.
Health Facilities
Specimen Collection, Delivery and Reporting
- COVID-19 Specimen Collection
- COVID-19 Lab Requisition Form
- COVID-19 Refrigerated Specimen Packaging
- COVID-19 Frozen Specimen Packaging
- COVID-19 Specimen Transport and Delivery
Specimen Reporting
SARS-CoV-2 Virus Strain Surveillance
- COVID-19 Enhanced Surveillance Submission Recommendations
- SARS-CoV-2 Enhanced Surveillance Submission Requisition Form 1198
Map and Directions for Laboratory Dropoff
The Dr. F.E.”ED” Thompson, Jr. Public Health Laboratory Facility is on the State Department of Health's central office campus in Jackson, MS at 350 East Woodrow Wilson Drive, Jackson, 39216.
Local Delivery of Samples: Drop samples off at the rear of the Thompson lab building. Detailed instructions are in our sample shipping guidance.
Dropoff hours: Monday through Friday from 8:00–4:30.
CDC Guidance
Healthcare and EMS
- Home Care Guidance
- Discontinuation of Home Isolation for Persons with COVID-19
- Healthcare Infection Control Guidance
- Clinical Care Guidance
- Healthcare Personnel with Potential COVID-19 Exposure Guidance
- Inpatient Obstetric Healthcare Guidance
- Guidance for EMS
Contact Tracing
- Contact Tracing Information and Guidance
- Collection and Submission of Postmortem Specimens from Deceased Persons with Confirmed or Suspected COVID-19
